DiaMedica Therapeutics Inc. (DMAC) stock
DMACNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.66−0.01 (-0.10%)
Close on Nov 11, 2026Market cap $520.92MP/E –Yield –
DiaMedica Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
DiaMedica Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $32.08M, up 31.6% year over year. For fiscal 2025 it was $24.61M, up 29.2% from the year before. The highest annual figure on record is $24.61M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.61M | +29.2% |
| FY2024 | Dec 31, 2024 | $19.06M | +45.4% |
| FY2023 | Dec 31, 2023 | $13.11M | +67.2% |
| FY2022 | Dec 31, 2022 | $7.84M | -10.6% |
| FY2021 | Dec 31, 2021 | $8.77M | +6.8% |
| FY2020 | Dec 31, 2020 | $8.21M | +3.9% |
| FY2019 | Dec 31, 2019 | $7.90M | +74.7% |
| FY2018 | Dec 31, 2018 | $4.52M | +41.0% |
| FY2017 | Dec 31, 2017 | $3.21M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $9.24M | +43.6% |
| Q2 FY2026 | Jun 30, 2026 | $8.15M | +40.0% |
| Q1 FY2026 | Mar 31, 2026 | $7.99M | +41.2% |
| Q4 FY2025 | Dec 31, 2025 | $6.70M | +3.5% |
| Q3 FY2025 | Sep 30, 2025 | $6.44M | +29.2% |
| Q2 FY2025 | Jun 30, 2025 | $5.82M | +48.2% |
| Q1 FY2025 | Mar 31, 2025 | $5.66M | +53.9% |
| Q4 FY2024 | Dec 31, 2024 | $6.47M | +76.0% |
| Q3 FY2024 | Sep 30, 2024 | $4.98M | +52.3% |
| Q2 FY2024 | Jun 30, 2024 | $3.93M | +54.5% |
| Q1 FY2024 | Mar 31, 2024 | $3.68M | +1.6% |
| Q4 FY2023 | Dec 31, 2023 | $3.68M | +62.0% |
| Q3 FY2023 | Sep 30, 2023 | $3.27M | +99.5% |
| Q2 FY2023 | Jun 30, 2023 | $2.54M | +30.1% |
| Q1 FY2023 | Mar 31, 2023 | $3.62M | +83.3% |
| Q4 FY2022 | Dec 31, 2022 | $2.27M | +21.3% |
| Q3 FY2022 | Sep 30, 2022 | $1.64M | -29.7% |
| Q2 FY2022 | Jun 30, 2022 | $1.96M | -9.3% |
| Q1 FY2022 | Mar 31, 2022 | $1.97M | -18.0% |
| Q4 FY2021 | Dec 31, 2021 | $1.87M | -39.6% |
| Q3 FY2021 | Sep 30, 2021 | $2.33M | +8.1% |
| Q2 FY2021 | Jun 30, 2021 | $2.16M | +34.7% |
| Q1 FY2021 | Mar 31, 2021 | $2.41M | +78.4% |
| Q4 FY2020 | Dec 31, 2020 | $3.10M | +71.9% |
| Q3 FY2020 | Sep 30, 2020 | $2.16M | +33.5% |
| Q2 FY2020 | Jun 30, 2020 | $1.60M | -14.6% |
| Q1 FY2020 | Mar 31, 2020 | $1.35M | -48.3% |
| Q4 FY2019 | Dec 31, 2019 | $1.80M | +24.2% |
| Q3 FY2019 | Sep 30, 2019 | $1.62M | +33.6% |
| Q2 FY2019 | Jun 30, 2019 | $1.87M | +75.1% |
| Q1 FY2019 | Mar 31, 2019 | $2.61M | +229.6% |
| Q4 FY2018 | Dec 31, 2018 | $1.45M | – |
| Q3 FY2018 | Sep 30, 2018 | $1.21M | – |
| Q2 FY2018 | Jun 30, 2018 | $1.07M | – |
| Q1 FY2018 | Mar 31, 2018 | $791.00K | – |
See a number that looks wrong?